Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
19.4M
-
Shares change
-
+566K
-
Total reported value, excl. options
-
$1.1B
-
Value change
-
+$34.2M
-
Put/Call ratio
-
0
-
Number of buys
-
48
-
Number of sells
-
-81
-
Price
-
$56.81
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q3 2021
158 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q3 2021.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.4M shares
of 27.8M outstanding shares and own 69.74% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.6M shares), FARALLON CAPITAL MANAGEMENT LLC (2M shares), ARMISTICE CAPITAL, LLC (1.84M shares), VANGUARD GROUP INC (1.8M shares), STATE STREET CORP (1.07M shares), FIRST MANHATTAN CO (970K shares), NORTHERN TRUST CORP (959K shares), Krensavage Asset Management, LLC (937K shares), RENAISSANCE TECHNOLOGIES LLC (757K shares), and DIMENSIONAL FUND ADVISORS LP (611K shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.